Market News & Trends
Unilife Signs Long-Term Commercial Supply Agreement for Use of Depot-jectTM Delivery System
Unilife Corporation recently announced the signing of a worldwide 10-year Commercial Supply Agreement with a global pharmaceutical company for the use of the Depot-jectTM delivery…
Juno Therapeutics Raises IPO Target to $191 Million
Seattle cancer-immunotherapy company Juno Therapeutics recently announced it has upped the target for its pending initial public offering of stock and gave the first indication…
iTeos Therapeutics Announces License & Collaboration With Pfizer
iTeos Therapeutics SA recently announced a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos’ preclinical compounds targeting…
Lightlake Therapeutics Announces Licensing Deal With Adapt Pharma Limited Subsidiary
LONDON, Dec. 16, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, recently…
Merck to Acquire Global Biopharmaceutical Company for Billions
Merck and Cubist Pharmaceuticals, Inc. recently announced the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share…
Hemispherx’s Ampligen Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
Philadelphia, PA, December 16, 2014: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) (the “Company” or “Hemispherx”), recently announced further progress on developing Ampligen® (rintatolimod) as a potential…
Angiochem Publishes Data for Treatment of Brain Metastases
Angiochem recently announced that ANG4043, a peptide-monoclonal antibody (mAb) conjugate, entered the brain at therapeutic concentrations, resulting in significantly prolonged survival in mice. The antibody…
Norwich Pharma Services Refines Business Strategy
Norwich, New York – December 16, 2014 – Norwich Pharma Services, a provider of contract manufacturing and clinical research services for the pharmaceutical industry, announced…
Top 30 Pharma Companies Spent $112 Billion on Research & Development in 2013
LONDON, UK (GlobalData), 16 December 2014 - The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013,…
Bioadhesives Poised to Replace Synthetic Solutions
The global bioadhesive industry is rapidly gaining prominence due to the evolution of biomaterials and the benefits of bioadhesives in a host of applications across…
Patent Cliff Means Pharmaceutical Companies Will Lose $65 Billion by 2019
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research…
Stem Cell Therapies Gathering Momentum But Significant Challenges Remain
LONDON, UK (GlobalData), 9 December 2014 - With 104 programs in late-stage clinical development, the stem cell therapy space could reach the commercialization threshold by…
ABIVAX Successfully Completes First-in-Man Study of Small Molecule Targeting HIV
ABIVAX recently announced the successful completion of its Phase I first-in-man study of ABX464, which has been designed to potentially deliver a number of important…
CTI BioPharma Receives $15-Million Milestone
CTI BioPharma Corp. recently announced that it has received a $15-million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales…
Catalent & Valerion Therapeutics to Collaborate
Catalent Pharma Solutions recently announced it is to collaborate with Valerion Therapeutics, LLC to develop Valerion’s two lead product candidates. The collaboration will focus on…
Hovione Files First IND Application With FDA
Hovione recenlty announced it has filed its first Investigational New Drug (IND) Application with the US FDA. This event represents a milestone in Hovione’s strategy…
Recipharm Acquires Flamel Technologies Sign Long-Term Collaboration
Recipharm AB (Jordbro) and Flamel Technologies SA (Lyon) recently announced they have entered into a long-term collaboration and signed an agreement whereby Recipharm will purchase…
Vetter Adds Flexible Serialization Service to its Portfolio
Vetter has recently announced a major milestone in the issue of drug safety. The contract development and manufacturing organization (CDMO) now offers the option of…
Horizon Discovery CEO Wins Executive of the Year Award
Cambridge, UK, 4th December 2014: Dr Darrin Disley, the Chief Executive Officer of Horizon Discovery Group plc (LSE: HZD) (Horizon), a leading provider of…
SciFluor Life Sciences Awarded US Patent for the Topical Treatment of Retinal Disease
Cambridge, Mass. (Dec. 4, 2014) - SciFluor Life Sciences, LLC, an emerging clinical-stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic…
